HDAC9 and T-cell non-Hodgkin lymphoma: Since these early studies, four HDAC inhibitors – Vorinostat, Romidepsin, Panobinostat, and Belinostat – have been approved by the US Food and Drug Administration (FDA) to treat T-cell lymphoma.